Progressive Amyloid-Related Imaging Abnormalities After Discontinuation of Lecanemab in Early Alzheimer Disease in an APOE ε2/ε4 Carrier. (PubMed, Eur J Neurol) - Oct 13, 2026 - "This case highlights that severe ARIA may progress beyond active treatment exposure and emphasizes the importance of continued MRI surveillance even after therapy cessation. Furthermore, the APOE ε2/ε4 genotype may represent a distinct risk factor for cerebral amyloid angiopathy-related vascular fragility and hemorrhagic ARIA."
Journal • Alzheimer's Disease • CNS Disorders • Hematological Disorders • APOE
|
|
Clemens Farr; Elisabeth Stögmann; Ellen Gelpi; Evelyn Berger Sieczkowski; Gregor Kasprian; Helena Untersteiner; Joel Leinkauf; Lukas Haider; Raphael Wurm; Sara Silvaieh; Tandis Parvizi; Thomas Berger; Thomas Nakuz
|